Andrew Mark Swensen - Publications

Affiliations: 
2000 Brandeis University, Waltham, MA, United States 

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Wang X, Liu B, Searle X, Yeung C, Bogdan AR, Greszler SN, Singh A, Fan Y, Swensen AM, Vortherms T, Balut C, Jia Y, Desino KE, Gao W, Yong H, et al. Discovery of 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis. Journal of Medicinal Chemistry. PMID 29251932 DOI: 10.1021/Acs.Jmedchem.7B01339  0.32
2016 Tang H, Zhu Y, Teumelsan N, Walsh SP, Shahripour A, Priest BT, Swensen AM, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Pai LY, Hampton C, Corona A, Hernandez M, et al. Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure. Acs Medicinal Chemistry Letters. 7: 697-701. PMID 27437080 DOI: 10.1021/acsmedchemlett.6b00122  1
2016 Walsh SP, Shahripour A, Tang H, de Jesus RK, Teumelsan N, Zhu Y, Frie J, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, et al. Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation. Bioorganic & Medicinal Chemistry Letters. PMID 27017115 DOI: 10.1016/j.bmcl.2016.03.035  1
2015 Walsh SP, Shahripour A, Tang H, Teumelsan N, Frie J, Zhu Y, Priest BT, Swensen AM, Liu J, Margulis M, Visconti R, Weinglass A, Felix JP, Brochu RM, Bailey T, et al. Discovery of a potent and selective ROMK inhibitor with pharmacokinetic properties suitable for preclinical evaluation Acs Medicinal Chemistry Letters. 6: 747-752. DOI: 10.1021/ml500440u  1
2014 Swensen AM, Niforatos W, Lee CH, Jarvis MF, McGaraughty S. Characterization of the triazine, T4, a representative from a novel series of CaV2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics. European Journal of Pharmacology. 745: 234-42. PMID 25446431 DOI: 10.1016/j.ejphar.2014.10.037  1
2014 Zhu CZ, Vortherms TA, Zhang M, Xu J, Swensen AM, Niforatos W, Neelands T, Milicic I, Lewis LG, Zhong C, Gauvin D, Mikusa J, Zhan C, Pai M, Roderwald V, et al. Mechanistic insights into the analgesic efficacy of A-1264087, a novel neuronal Ca(2+) channel blocker that reduces nociception in rat preclinical pain models. The Journal of Pain : Official Journal of the American Pain Society. 15: 387.e1-14. PMID 24374196 DOI: 10.1016/J.Jpain.2013.12.002  1
2014 Xu J, Chu KL, Zhu CZ, Niforatos W, Swensen A, Searle X, Lee L, Jarvis MF, McGaraughty S. A mixed Ca2+ channel blocker, A-1264087, utilizes peripheral and spinal mechanisms to inhibit spinal nociceptive transmission in a rat model of neuropathic pain. Journal of Neurophysiology. 111: 394-404. PMID 24155005 DOI: 10.1152/Jn.00463.2013  1
2014 Garcia ML, Priest BT, Alonso-Galicia M, Zhou X, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Liu J, Swensen A, Pai LY, Xiao J, Hernandez M, Hoagland K, Owens K, et al. Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis. The Journal of Pharmacology and Experimental Therapeutics. 348: 153-64. PMID 24142912 DOI: 10.1124/jpet.113.208603  1
2013 Shao PP, Ye F, Chakravarty PK, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, Green M, et al. Improved Cav2.2 Channel Inhibitors through a gem-Dimethylsulfone Bioisostere Replacement of a Labile Sulfonamide. Acs Medicinal Chemistry Letters. 4: 1064-8. PMID 24900606 DOI: 10.1021/ml4002612  1
2013 Tang H, de Jesus RK, Walsh SP, Zhu Y, Yan Y, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, Pai LY, Hampton C, et al. Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one. Bioorganic & Medicinal Chemistry Letters. 23: 5829-32. PMID 24075732 DOI: 10.1016/j.bmcl.2013.08.104  1
2013 Beebe X, Yeung CM, Darczak D, Shekhar S, Vortherms TA, Miller L, Milicic I, Swensen AM, Zhu CZ, Banfor P, Wetter JM, Marsh KC, Jarvis MF, Scott VE, Schrimpf MR, et al. Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain. Bioorganic & Medicinal Chemistry Letters. 23: 4857-61. PMID 23876987 DOI: 10.1016/J.Bmcl.2013.06.074  1
2013 Hermann D, Mezler M, Swensen AM, Bruehl C, Obergrußerger A, Wicke K, Schoemaker H, Gross G, Draguhn A, Nimmrich V. Establishment of a secondary screening assay for P/Q-type calcium channel blockers. Combinatorial Chemistry & High Throughput Screening. 16: 233-43. PMID 23228050 DOI: 10.2174/1386207311316030008  1
2012 Shao PP, Ye F, Chakravarty PK, Varughese DJ, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, et al. Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain. Journal of Medicinal Chemistry. 55: 9847-55. PMID 23098566 DOI: 10.1021/jm301056k  1
2012 Beebe X, Darczak D, Henry RF, Vortherms T, Janis R, Namovic M, Donnelly-Roberts D, Kage KL, Surowy C, Milicic I, Niforatos W, Swensen A, Marsh KC, Wetter JM, Franklin P, et al. Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity. Bioorganic & Medicinal Chemistry. 20: 4128-39. PMID 22626552 DOI: 10.1016/j.bmc.2012.04.057  1
2012 Swensen AM, Niforatos W, Vortherms TA, Perner RJ, Li T, Schrimpf MR, Scott VE, Lee L, Jarvis MF, McGaraughty S. An automated electrophysiological assay for differentiating Ca(v)2.2 inhibitors based on state dependence and kinetics. Assay and Drug Development Technologies. 10: 542-50. PMID 22428804 DOI: 10.1089/adt.2011.437  1
2012 Mezler M, Hermann D, Swensen AM, Draguhn A, Terstappen GC, Gross G, Schoemaker H, Freiberg G, Pratt S, Gopalakrishnan SM, Nimmrich V. Development and validation of a fluorescence-based HTS assay for the identification of P/Q-type calcium channel blockers. Combinatorial Chemistry & High Throughput Screening. 15: 372-85. PMID 22272661 DOI: 10.2174/138620712800194503  1
2012 Swensen AM, Herrington J, Bugianesi RM, Dai G, Haedo RJ, Ratliff KS, Smith MM, Warren VA, Arneric SP, Eduljee C, Parker D, Snutch TP, Hoyt SB, London C, Duffy JL, et al. Characterization of the substituted N-triazole oxindole TROX-1, a small-molecule, state-dependent inhibitor of Ca(V)2 calcium channels. Molecular Pharmacology. 81: 488-97. PMID 22188924 DOI: 10.1124/Mol.111.075226  1
2012 Scott VE, Vortherms TA, Niforatos W, Swensen AM, Neelands T, Milicic I, Banfor PN, King A, Zhong C, Simler G, Zhan C, Bratcher N, Boyce-Rustay JM, Zhu CZ, Bhatia P, et al. A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats. Biochemical Pharmacology. 83: 406-18. PMID 22153861 DOI: 10.1016/j.bcp.2011.10.019  1
2011 Vortherms TA, Swensen AM, Niforatos W, Limberis JT, Neelands TR, Janis RS, Thimmapaya R, Donnelly-Roberts DL, Namovic MT, Zhang D, Brent Putman C, Martin RL, Surowy CS, Jarvis MF, Scott VE. Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 60: 683-93. PMID 21394563 DOI: 10.1007/s00011-011-0322-9  1
2011 Tyagarajan S, Chakravarty PK, Park M, Zhou B, Herrington JB, Ratliff K, Bugianesi RM, Williams B, Haedo RJ, Swensen AM, Warren VA, Smith M, Garcia M, Kaczorowski GJ, McManus OB, et al. A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain. Bioorganic & Medicinal Chemistry Letters. 21: 869-73. PMID 21195616 DOI: 10.1016/j.bmcl.2010.11.067  1
2010 Schmalhofer WA, Swensen AM, Thomas BS, Felix JP, Haedo RJ, Solly K, Kiss L, Kaczorowski GJ, Garcia ML. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel. Assay and Drug Development Technologies. 8: 714-26. PMID 21158686 DOI: 10.1089/adt.2010.0351  1
2010 Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ, Herrington JB, Kaczorowski GJ, Smith MM, Swensen AM, Warren VA, Williams B, Arneric SP, Eduljee C, Snutch TP, et al. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. The Journal of Pharmacology and Experimental Therapeutics. 334: 545-55. PMID 20439438 DOI: 10.1124/Jpet.110.166363  1
2008 Weinglass AB, Swensen AM, Liu J, Schmalhofer W, Thomas A, Williams B, Ross L, Hashizume K, Kohler M, Kaczorowski GJ, Garcia ML. A high-capacity membrane potential FRET-based assay for the sodium-coupled glucose co-transporter SGLT1. Assay and Drug Development Technologies. 6: 255-62. PMID 18471079 DOI: 10.1089/Adt.2008.125  1
2008 Dai G, Haedo RJ, Warren VA, Ratliff KS, Bugianesi RM, Rush A, Williams ME, Herrington J, Smith MM, McManus OB, Swensen AM. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay and Drug Development Technologies. 6: 195-212. PMID 18471074 DOI: 10.1089/adt.2008.136  1
2007 Richards KS, Swensen AM, Lipscombe D, Bommert K. Novel CaV2.1 clone replicates many properties of Purkinje cell CaV2.1 current. The European Journal of Neuroscience. 26: 2950-61. PMID 18001290 DOI: 10.1111/J.1460-9568.2007.05912.X  1
2007 Priest BT, Swensen AM, McManus OB. Automated electrophysiology in drug discovery. Current Pharmaceutical Design. 13: 2325-37. PMID 17692004 DOI: 10.2174/138161207781368701  1
2005 Swensen AM, Bean BP. Robustness of burst firing in dissociated purkinje neurons with acute or long-term reductions in sodium conductance. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 3509-20. PMID 15814781 DOI: 10.1523/Jneurosci.3929-04.2005  1
2003 Swensen AM, Bean BP. Ionic mechanisms of burst firing in dissociated Purkinje neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 9650-63. PMID 14573545 DOI: 10.1523/Jneurosci.23-29-09650.2003  1
2001 Swensen AM, Marder E. Modulators with convergent cellular actions elicit distinct circuit outputs. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 4050-8. PMID 11356892 DOI: 10.1523/Jneurosci.21-11-04050.2001  1
2001 Nusbaum MP, Blitz DM, Swensen AM, Wood D, Marder E. The roles of co-transmission in neural network modulation. Trends in Neurosciences. 24: 146-54. PMID 11182454 DOI: 10.1016/S0166-2236(00)01723-9  1
2000 Swensen AM, Marder E. Multiple peptides converge to activate the same voltage-dependent current in a central pattern-generating circuit. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 6752-9. PMID 10995818 DOI: 10.1523/Jneurosci.20-18-06752.2000  1
2000 Swensen AM, Golowasch J, Christie AE, Coleman MJ, Nusbaum MP, Marder E. GABA and responses to GABA in the stomatogastric ganglion of the crab Cancer borealis. The Journal of Experimental Biology. 203: 2075-92. PMID 10862721  1
Show low-probability matches.